CRScube`s Commitment to Global Partners

The COVID-19 pandemic emphasized and exacerbated health inequities from around the world and has impacted many aspects of our lives, including how and where we work. Despite the rapid successes in vaccine development, the Drug Authorities such as the FDA in the U.S. and WHO have both recommended additional studies to assess how effective the vaccines are after issuing emergency approval for their use and this is very important to address the existing gaps in medical information.

Here at CRScube, our teams in China, Japan, South Korea, and the U.S. have been working around the clock with our partners (ie., CROs, Biotech`s, Pharmaceuticals, Global Health, etc.) across the globe to meet the need for COVID-19 related studies and meeting critical study timelines and milestones.

For the past 18-months, CRScube has been hard at work with partners in Sub-Saharan Africa to address the substantial impact that COVID-19 has had on the regulatory landscape to enable CROs, Global Health, Pharma, Biotech, and clinical sites to conduct all phases of clinical trials in settings with limited internet connectivity. Of note, CRScube along with clinical sites located in multiple countries successfully tested cubeSolutions (i.e., cubeCDMS®, cubeIWRS®, cubeTMF®, cubeSAFETY®, etc.) in regions with limited internet connectivity. The site staff that participated in the test reported no issues of connectivity to any of cubeSolutions.

CRScube will continue to work with our partners and support their clinical trial needs and requirements.